摘要
目的观察腹水超滤浓缩回输系统联合速尿、多巴胺腹腔注射治疗肝硬化难治性腹水的临床疗效及安全性。方法将我院56例肝硬化难治性腹水患者随机分为两组。对照组采用腹水超滤浓缩治疗,治疗组在腹水超滤浓缩治疗基础上加用速尿、多巴胺腹腔内注射联合治疗,比较两组疗效,并随诊3个月和6个月。结果治疗组近期总有效率为92.85%,对照组为60.71%,二者差异有高度统计学意义(P<0.01)。治疗停止后3个月随访,治疗组总有效率为82.14%,对照组总有效率32.14%,二者差异有高度统计学意义(P<0.01),6个月随访,治疗组总有效率为78.57%,对照组总有效率为25.00%,二者差异有高度统计学意义(P<0.01)。两组不良反应均少见且可耐受,不影响治疗。结论腹水超滤浓缩回输联合速尿、多巴胺腹腔内注射治疗肝硬化难治性腹水安全、疗效好。
Objective To observe the clinical efficacy and safety of ascites reinfusion ultrafiltration system combined Furosemide,Dopamine intraperitoneal injection on patients with refractory ascites secondary to liver cirrhosis.Methods 56 patients of liver cirrhosis were randomly divided into two groups.The control group were treated with ascites ultrafiltration,The treatment group were treated additionally with Furosemide,Dopamine intraperitoneal injection.Results Effective rate in treatment group was significantly higher than that in control group（92.85% vs 60.71%,P 0.01）.The difference in effective rate remained between treatment group and control group after three months follow up（82.14% vs 32.14%,P 0.01） and 6 months follow up（78.57% vs 25.00 %,P 0.01）.Conclusion Ascites reinfusion ultrafiltration combined Furosemide and Dopamine intraperitoneal injection is safety and efficiency in the treatment of refractory cirrhotic ascites.
出处
《中国医药导报》
CAS
2012年第8期30-31,共2页
China Medical Herald
